Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation

Kaibo Ding; Zhongsheng Peng; Yanjun Xu

doi:10.1016/j.gendis.2024.101408

| Sign up

PDF (613.3 KB)

Cite

EndNote(RIS) BibTeX

Collect

Submit Manuscript

Show Outline

Outline

References

Show full outline

Hide outline

Letter | Open Access

Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation

Kaibo Ding^{^a^,^b}, Zhongsheng Peng^{^a^,^b}, Yanjun Xu^{^a}()

Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China

Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China

Peer review under the responsibility of the Genes & Diseases Editorial Office, in alliance with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA).

Show Author Information

References

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94.

Crossref Google Scholar

Lu C, Wei XW, Wang Z, et al. Allelic context of EGFR C797X-mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes. J Thorac Oncol. 2024;19(4):601–612.

Google Scholar

Shi Y, Zhang S, Hu X, et al. Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J Thorac Oncol. 2020;15(6):1015–1026.

Google Scholar

Starrett JH, Guernet AA, Cuomo ME, et al. Drug sensitivity and allele specificity of first-line osimertinib resistance EGFR mutations. Cancer Res. 2020;80(10):2017–2030.

Crossref Google Scholar

Li M, Qin J, Xie F, Gong L, Han N, Lu H. L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment. Discov Oncol. 2022;13(1):72.

Crossref Google Scholar

Genes & Diseases

Volume 12 Issue 2,
March 2025

Article number: 101408

DOI: 10.1016/j.gendis.2024.101408

Cite this article:

Ding K, Peng Z, Xu Y. Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation. Genes & Diseases, 2025, 12(2): 101408. https://doi.org/10.1016/j.gendis.2024.101408